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Edited by Berend WieringaAbstract Mutations of SGCE encoding e-sarcoglycan cause
myoclonus-dystonia. SGCE is paternally expressed; however,
5–10% of patients show maternal inheritance of the disease.
We found Sgce was exclusively paternally expressed in mice
by using a novel polymorphism marker. The result was conﬁrmed
in Sgce heterozygous knockout mice. This ﬁnding suggests that
maternally inherited myoclonus-dystonia may not result from
maternal expression of SGCE. Furthermore, we report a new
family of alternatively spliced Sgce mRNA expressed in the
brain coding for diﬀerent C-terminal sequences possessing a
PDZ-binding motif. Our results provide a better basis for
diagnosis and understanding of the pathogenesis of myoclonus-
dystonia.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Human SGCE encodes e-sarcoglycan, a transmembrane
protein that is expressed in many tissues including the brain,
muscle, and placenta [1,2]. Mutations in SGCE have been
associated with DYT11 dystonia, or myoclonus-dystonia
[3,4] characterized by myoclonic jerks of rapid muscle contrac-
tions and dystonic postures with sustained twisting and repet-
itive movements [5]. Dystonia is generally believed to be a
disorder of the central nervous system [6]. DYT11 patients also
show psychiatric features such as panic attacks, personality
disorders, and obsessive compulsive disorders [7], further sug-
gesting the eﬀects of SGCE mutation are likely localized to the
central nervous system. Penetrance of DYT11 dystonia
depends highly on the parental origin of the disease allele. AAbbreviations: UTR, untranslated region; SGCE or Sgce, e-sarcogly-
can gene; RT-PCR, reverse transcriptase-PCR
q The nucleotide sequences reported in this paper have been submitted
to the DDBJ/EMBL/GenBank databases with Accession Nos. of
AB200281 for e-SG8+11c+ and AB200282 for e-SG811c+.
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from their father, while 5–10% inherit it from their mother
[4,8,9]. SGCE is shown to be maternally imprinted using blood
DNA and RNA samples [9,10]. Its imprinting pattern in the
brain is unknown. Genetic heterogeneity and the diﬃculty of
obtaining human brain DNA and RNA samples necessitate
an alternative mammalian system to study the regulation of
SGCE imprinting.
Genomic sequencing of both human and mouse have been
completed. The similarity of mouse and human genomes
makes mouse a useful mammalian system to study the genes
involved in human neurological disorders. Mouse e-sarcogly-
can cDNA was originally cloned as a homologue of a-sarco-
glycan [11,12]. Mouse e-sarcoglycan is widely expressed in
the body and replaces a-sarcoglycan in smooth muscles to
form a unique dystrophin-glycoprotein complex [13]. Sgce is
localized to the proximal region of chromosome 6 next to
the Peg10 gene in the head-to-head position and share the
same diﬀerentially methylated regions [14]. Although the
paternal allele of Sgce is predominantly expressed in the brain,
heart and kidney, the maternal allele is also weakly expressed
in the brain in an adult interspeciﬁc hybrid mouse ofMus mus-
culus and Mus spretus [15]. Peg10 expression, on the other
hand, is completely paternally directed in Mus musculus
intraspeciﬁc F1 hybrids derived from JF1 and C57BL/6 strains
[14]. It is not known to what extent maternal expression of e-
sarcoglycan occurs in the brain, which is crucial to understand-
ing the penetrance and pathogenesis of DYT11 dystonia.
We analyzed Sgce expression in Mus musculus intra speciﬁc
F1 hybrid brains and found that in contrast to the published
partial maternal expression of e-sarcoglycan, the expression
of Sgce was exclusively paternally directed. While studying
the imprinting of the Sgce gene, we have also identiﬁed alter-
native splicing variant mRNAs for e-sarcoglycans in the brain
and report the characterization of these variants.2. Materials and methods
2.1. Identiﬁcation of a polymorphism in Sgce 3 0-UTR between
C57BL/6 and 129/Sv
Genomic DNA of C57BL/6 mice, 129/Sv ES cells, and intraspeciﬁc
F1 hybrid mice derived from a cross between C57BL/6 and 129/Sv
was extracted from the cells or isolated from the tails as previously de-
scribed [16]. A fragment covering Sgce 3 0-UTR was ampliﬁed by PCR
using AmpliTaq DNA Polymerase Stoﬀel Fragment (Applied Biosys-
tems) with Sgce3P5 and Sgce3P3 primers. The PCR products were
either directly sequenced or cloned into plasmid and sequenced. Primer
sequences, their locations and annealing temperatures for PCR are
summarized in Table 1.ation of European Biochemical Societies.
Table 1
Primers and their annealing temperature for the PCRs
Primer name Location Sequence (5 0 ﬁ 3 0) Temp. (C)
Sgce3P5 I11+ TATGTTCAAGAGCTAAACGTGCC 64
Sgce3P3 I12 CCTTGGACCTAGTACAGACGTTA 64
Sgce1 I2/E3+ ATCTAGGGGAGGTTAGTAATGAT 54
Sgce2 I3 TCTCTCAGATCTTCAGGGCCAAG 54
S32 I5+ CCGAGTGACACATATGTTTGC 45
S31 I5 ACTTAATGCGTCATAAGCGCT 45
SgceloxP5 I4+ GAGATCTTAGTCTACAGTTGGACC 66
SgceloxP3 I4 CATACTGTTTGGGGTCACTTAACC 66
pgkp P TCCATCTGCACGAGACTAGTGAG 66
SgceE4U I3+ CTGTAACAACACACTGGAGTAG 63
SgceE4D I4 ACAGCTTTGAACTACTTTGTGCA 63
SgceExon4P E4+ AATAGACGTACCTTTGAGACTGC 63
SgceExon6RP E6 CTTGCACCAGTCGATATGAAAG 63
SgceExon9 E9+ CTACCAAGGAGCTTCGAGACATG 54
Sgce3UTR1 E12 CAAATATAAAGTCGTTGATGTCT 54
p5UTR E12+ TGGTATCCCTGAAGAAAGAAAGCTG –a
Sgce5UTR2 E1+ GGAAAGGGTCGGGGGACACTC 54, 58b
36U E11c TTCCCGAGAGCAGTAATAGAGGAG 58, 62c
36D E11c+ CCTCTATTACTGCTCTCGGGAA 66
SgceIntRP I11 TGATTTCTACTCATTGCACGCCAC 66
976 E7+ GCTTATATCATGTGCTGCCGA 62
Temp.: annealing temperature. In the location column, I: intron; E: exon, +: sense strand sequence; : antisense strand; P: PGKneo cassette.
aPrimer p5UTR was for sequencing.
b54C when used with primer Sgce3UTR1 and 58C with 36U.
c62C when used with primer 976.
F. Yokoi et al. / FEBS Letters 579 (2005) 4822–4828 48232.2. Making of Sgce knockout mice
The Sgce gene was isolated from a RPCI-22 BAC library made
from 129/SvEvTACBr mice at The Center for Applied Genomics,
The Hospital for Sick Children, Toronto, Ont., Canada. The RPCI-
22 BAC library was originally constructed in the laboratory of Pieter
de Jong at the Roswell Park Cancer Institute in Buﬀalo, NY. A 14-kb
NcoI–SalI fragment encoding exons 4 and 5 was subcloned. A con-
struct was made with two loxP sites ﬂanking exon 4 [17,18]. The con-
struct was transfected into D3 129/Sv ES cells and the appropriate
recombination was conﬁrmed by Southern blot analysis [19]. DNA
fragments for the 5 0 and 3 0 probes were synthesized by PCR using pri-
mer sets of Sgce1 and Sgce2, and of S32 and S31, respectively. The
transfectants were microinjected into C57BL/6 blastocysts [20]. Chi-
merical mice were made and crossed with C57BL/6 females to trans-
mit the germline of the targeted mutation. Exon 4 was deleted by
crossing with CMV-cre mice (Jackson Laboratory, Stock No.
003465) [21]. The progenies carrying both cre and Sgce loxP deleted
loci (D) with neomycin cassette (PGKneo) were mated with FLP mice
(Jackson Laboratory, Stock No. 003946) to remove the cassette [22].
Mice heterozygous for Sgce deleted loci (D) were intercrossed to pro-
duce Sgce knockout homozygous (D/D) mice. A Sgce +/D male was
crossed with a C57BL/6 female to obtain paternally inherited Sgce
+/D mice. The genotypes were conﬁrmed by PCR using SgceloxP5
and SgceloxP3 primers for detecting exon 4 and loxP site, pgkp and
SgceloxP3 primers for the deleted exon 4 locus and neomycin cassette,
and SgceE4U and SgceE4D primers for the deleted exon 4 locus with-
out the cassette. Brain RNA was prepared from the Sgce knockout
(D/D) and wild-type mice with the RNeasy Protect Midi Kit (Qiagen).
The amount of RNA was determined by its 260 nm absorbance. Sgce
expression in the brain was analyzed by RT-PCR for 40 cycles of
ampliﬁcation using QIAGEN OneStep RT-PCR Kit and SgceExon4P
and SgceExon6RP as primers. The DNA fragments were separated on
a 1.5% agarose gel.
2.3. Direct sequencing of RT-PCR products of e-sarcoglycan mRNA
3 0-UTR from the brains of F1 hybrid and RT-PCR analysis
of Sgce +/D mice
F1 hybrid mice derived from 129/Sv females and C57BL/6 males
were used to determine which Sgce allele was expressed based on
their polymorphism. Thirty one female and 10 male from 10 days
to 100 days postnatal were obtained from 11 litters. RNA was pre-
pared from the F1 hybrid, paternally inherited Sgce +/D, and wild-
type mouse brains. For sequencing of the RT-PCR products fromthe F1 hybrids, RT-PCR was performed with SgceExon9 and
Sgce3UTR1 primers that would cover all types of mRNA variants.
The RT-PCR products were puriﬁed and directly sequenced with
p5UTR and/or Sgce3UTR1 primers. For analysis of the maternal
expression of Sgce, 10 ng each of RNA prepared from three pater-
nally inherited Sgce +/D and three wild-type mouse brains was used
as template for RT-PCR for 40 cycles of ampliﬁcation using Sgce-
Exon4P and SgceExon6RP as primers. The DNA fragments were
separated on a 1.5% agarose gel.2.4. Identiﬁcation of e-sarcoglycan mRNAs encoding three
diﬀerent types of C-terminal sequences in the brain
Brain RNA was prepared from C57BL/6, 129/Sv, or their F1 hy-
brid mice. RNA was also prepared from the heart, lung and kidney
of the F1 hybrid mice. RT-PCR was performed with SgceExon9 and
Sgce3UTR1 primers that ampliﬁed all three types of variants. The
ampliﬁed DNA fragments were separated, isolated from a 4% aga-
rose gel, and cloned into the plasmid. The plasmid DNAs were puri-
ﬁed and sequenced.2.5. Molecular cloning of cDNAs encoding the novel alternatively spliced
variants
Total RNA was prepared from the F1 hybrid mouse brain and
RT-PCR was performed using Sgce3UTR1 and Sgce5UTR2 primers.
The RT-PCR products were separated on an agarose gel and the
DNA fragments were isolated and ligated into the plasmid. The
cDNA clones encoding type 3 were selected by PCR analysis using
Sgce5UTR2 and 36U primers. Plasmids were puriﬁed and sequenced.
Splice sites of Sgce were identiﬁed using the public mouse genome
server. For veriﬁcation of the genomic DNA sequence at the exon/in-
tron junction downstream of the novel exon 11c, genomic DNA was
puriﬁed from the tail of a C57BL/6 mouse and the corresponding se-
quence was ampliﬁed by PCR using 36D and SgceIntRP primers.
The PCR product was cloned into the plasmid and sequenced. To
compare the expression of two subtypes of type 3 with or without
exon 8 in the parental inbred strains, we isolated RNA from
C57BL/6, 129/Sv, or their F1 hybrid mouse brains and performed
RT-PCR with 976 [23] and 36U primers. Two isolated clones con-
taining either e-SG8+11c+ or e-SG811c+ were used as templates
for PCR with 976 and 36U primers to produce control ladders for
each subtype. The RT-PCR and PCR products were separated on
a 4% agarose gel.
Fig. 1. Polymorphism of Sgce 3 0-UTR and analysis of Sgce mRNA in
the F1 hybrid brains. In the Sgce 3 0-UTR, eight consecutive thymines
were found in C57BL/6 mice (A), seven consecutive thymines in 129/Sv
mice (B), and a mixed sequence of eight and seven thymines (arrow
shows the extra T); (C) in the F1 hybrid mice. A representative
sequence (D) from the 41 sequenced RT-PCR products of the F1
hybrid brains showed only cDNA with eight thymines, indicating that
only the paternal C57BL/6-derived allele was expressed.
Fig. 2. Making of Sgce loxP mice. (A) Map of targeting construct,
Sgce wild-type (WT) and mutant (MT) alleles. Filled boxes indicate
exons. The targeting construct was made with two loxP sites (ﬁlled
triangles) ﬂanking exon 4 with a reversely directed PGKneo cassette
without a polyA sequence (open left arrow). The PGKneo cassette was
ﬂanked by FRT sites (open triangles). The locations of 5 0 and 3 0 probes
were indicated above the map and predicted restriction fragments sizes
were depicted below the map. N, NcoI; S, SalI; H, HindIII; B, BamHI.
(B) Southern blots analysis of the transfectants. The genomic DNAs
digested by HindIII or BamHI were hybridized with 5 0 probe or 3 0
probe, respectively. Two correctly targeted clones (1 and 3) were
selected. The false positive clones (2 and 4–6; FP) with only left loxP
site were produced by an undesirable recombination between the two
loxP sites.
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The Sgce 3 0-UTR sequence in C57BL/6 had one more con-
secutive thymine than that of 129/Sv (Fig. 1A and B). The se-
quence of their F1 hybrid genomic DNA revealed a mixed
sequence of comparable signal intensity between the two al-
leles, providing a sensitive mean to detect the maternal or
paternal expression of the Sgce mRNA (Fig. 1C). If both
parental mRNAs were expressed, the mixed sequence pattern
would be detected. Forty one F1 hybrid mice produced by
crossing C57BL/6 males and 129/Sv females were analyzed
for their Sgce expression in the brain. The direct sequencing
of the RT-PCR products revealed that all sequences encoded
the consecutive eight thymines derived from their paternal
C57BL/6-type allele without any other peaks corresponding
to the maternal 129/Sv transcripts (Fig. 1D). The results sug-
gested that the paternal alleles were exclusively expressed in
the brains of Mus musculus intraspeciﬁc hybrid mice.
To investigate whether the residual amount of Sgce was ex-
pressed from the maternally inherited allele, we analyzed Sgceknockout mice using embryonic stem cell-based gene targeting.
A construct was made with two loxP sites ﬂanking exon 4 (73 bp
long; Fig. 2A). Two targeted mouse ES cell clones were isolated
from 130 clones (Fig. 2B). Chimerical mice were obtained by the
microinjection methods and then Sgce loxP mice were obtained
by the breeding. The Sgce exon 4 and neomycin cassette were
deleted by crossing with CMV-cre mice and FLP mice
(Fig. 3). TheSgce heterozygous knockoutmice (+/D) were inter-
crossed to produce theSgce knockout (D/D) mice with both cop-
ies of the Sgce gene inactivated. RT-PCR analysis for exon 4 of
the brain RNA from the Sgce knockout mice (D/D) failed to de-
tect Sgce mRNA suggesting we have inactivated Sgce success-
fully (Fig. 4A). Deletion of exon 4 would cause a frame shift
and create a premature stop codon in exon 5 when splicing oc-
curs between exons 3 and 5. The mutant SgcemRNA should be
unstable and degraded through non-sense-mediated mRNA
decay [24]. Similar to human DYT11 patients, the Sgce knock-
out mice exhibited signiﬁcantly increased myoclonus and deﬁ-
cits in motor coordination and balance. Details of their
phenotypic characterization will be published elsewhere.
Sgce mRNA expression in the paternally inherited Sgce +/D
mice produced by crossing a Sgce +/D male with a C57BL/6
female was analyzed. Although RT-PCR to detect exon 4
Fig. 3. Making of Sgce knockout mice. (A) A line of Sgce loxP mice
was obtained as shown above. Filled triangles indicate loxP sites
inserted. Open triangles indicate the FRT sites that were incorporated
to remove the PGKneo cassette without a polyA sequence (open left
arrow). Exon 4 and PGKneo were removed by crossing with CMV-Cre
and FLP transgenic mice, respectively. The loss of exon 4 induced a
frame shift in exon 5 when splicing occurs between exons 3 and 5. (B)
Detection of exon 4-deleted and wild-type loci by PCR-based
genotyping. The primer sites to amplify the exon 4-containing locus
(+) and exon 4-deleted locus (D) were shown in (A) by closed and open
arrow pairs, respectively. In the Sgce knockout (D/D) mouse, only the
deleted loci were detected.
Fig. 4. Analysis of the Sgce expression mode using the knockout mice.
(A) RT-PCR analysis of brain RNA from wild-type (+/+) mice and
Sgce knockout (D/D) mice using primers located in exons 4 and 6. No
RT-PCR product was detected in the Sgce D/D mouse. (B) RT-PCR
analysis of brain RNA from three wild-type (+/+) mice and three
paternally inherited Sgce +/D mice using the same primers. Arrow
indicates the 414-bp products observed only in the wild-type mice.
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414-bp products, no such bands could be detected from pater-
nally inherited Sgce +/D brains. These results further conﬁrm
that the paternal alleles were exclusively expressed in the brains
(Fig. 4B).
While searching for a polymorphism at 3 0-UTR of Sgce, we
found that RT-PCR products from the mouse brain RNA for
the C-terminal region were separated into three bands by elec-
trophoresis while only a single band was present in the lungs
(Fig. 5A). To analyze the tissue distribution of each variant
further, we prepared and analyzed total RNA from the heart
and kidney. These results suggested that type 2 and type 3 were
mainly expressed in the brain. The same distribution of those
variants was detected in C57BL/6 and 129/Sv, two parental
inbred strains of the F1 hybrid mice (Fig. 5B).
Sequence analysis of the three fragments showed that they
corresponded to three types of alternative splicing variants for
diﬀerent putative C-terminal ends of e-sarcoglycan (Fig. 6A).
Type 1 corresponded to the originally reported e-sarcoglycan.
Type 2 corresponded to the recently reported alternative splic-
ing variant containing exon 11b [23]. Type 3 was a novel alter-
native splicing variant with a new exon we named 11c. Two
subtypes of clones encoding the type 3 C-terminal sequences
were isolated that were either with or without exon 8
(Fig. 6B) similar to what have been reported for type 1 and type
2 C-terminal sequences [23]. We named these two mRNA vari-ants as e-SG8+11c+ and e-SG811c+, respectively. These two
variants were detected in the brains of their parental inbred
strains as well (Fig. 6C). We searched the public mouse genome
database and found a GC sequence instead of GT at the exon/
intron junction downstream of the exon 11b and exon 11c. This
was veriﬁed by sequencing. GC-AG intron splicing occurs in
only 0.69% of human splice sites [25]. The results suggested that
mRNAs for type 2 and type 3 C-terminal sequences were pro-
duced by combination of GU-AG and GC-AG intron splicing.
When the alternative splicing for type 2 C-terminal sequence oc-
curs, the 36-bp exon region in the exon 11c for type 3 is skipped.
We analyzed the motifs in three C-terminal sequences that
could potentially be encoded by alternative splicing and no-
ticed that type 2 and type 3 C-terminal sequences were similar
to PDZ-binding motifs, which bind to PDZ domain of the
scaﬀold proteins. PDZ-binding motifs are divided into three
classes according to their consensus sequences [26,27]. The
type 3 C-terminal sequence of LSGI was similar to the class
I with X-S/T-X-V/L/I (X, unspeciﬁed amino acid). The type
2 C-terminal sequence of AMSL was similar to the class II do-
main typically with X-/-X-/ (/, hydrophobic amino acid).4. Discussion
While SGCE expression is generally believed to be paternally
directed, there have been conﬂicting ﬁndings reported. In the
Fig. 5. RT-PCR products corresponding to Sgce alternative splicing
variants at the C-terminal sequence. (A) Five representative RT-PCR
samples using brain or lung RNA from F1 hybrid mice. The marker
bands (M) are on the left. (B) RT-PCR products using RNAs from the
brain, heart, lung and kidney. Three types of alternative splicing
variants were detected in the brains of the F1 hybrid mice and their
parental inbred strains. The locations of the primers used are depicted
as closed arrowheads in Fig. 6B.
Fig. 6. Partial map of the Sgce gene and its alternative splicing
variants. (A) Predicted C-terminal amino acid sequences of e-sarco-
glycans generated by alternative splicing (italics). (B) Schematic
presentation of the three alternatively spliced variants with and
without exon 8. The variant without 71-bp exon (36- and 35-bp) is the
originally reported type 1. The variant with 35-bp exon (exon 11b) is
the recently reported type 2. The variant with 71-bp exon (exon 11c)
was the novel type 3. All of the three types had two subtypes with or
without exon 8. Exon 10 reported in human SGCE is missing in mouse
Sgce. Closed and open arrowheads indicate the primer sites used for
the RT-PCR shown in Fig. 5 and (C) of this ﬁgure, respectively. Closed
boxes indicate translated regions. Open boxes indicate untranslated
regions. T8/T7 indicates the polymorphism region between C57BL/6
and 129/Sv. (C) RT-PCR using primers located in exons 7 and 11c (36-
bp region) demonstrated the expression of the two subtypes, with or
without exon 8, in the brains of the parental inbred strains as well as
their hybrid. PCR products of cDNA clones containing either
e-SG8+11c+ or e-SG811c+ variant were used as controls (right two
lanes).
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is detected in the brain [15]. Additionally, a patient was found
to express both the mutated and wild-type alleles in blood cells
[10]. We have demonstrated that this incomplete maternal
imprinting did not exist with Sgce in intraspeciﬁc mouse
brains. Although the experiments could not exclude the possi-
bility of an undetectable low level of minor maternal expres-
sion leakage, it is clear that the same level of maternal allele
expression observed in the interspeciﬁc hybrid mouse brain
did not occur in the intraspeciﬁc F1 hybrid mouse.
The exclusive paternal expression of the Sgce matched the
all-or-none paternal expression in the intraspeciﬁc mouse brain
of Peg10 that shares the same CpG islands with Sgce [14].
Thus the maternal expression reported in mice [15] may be
caused by a collapse of the imprinting system in the interspe-
ciﬁc hybrid. Discrepancies between the interspeciﬁc and
intraspeciﬁc hybrid mice are also evident in cases with mito-
chondrial DNA transmission. Paternal mitochondrial DNA
transmission is detected in the interspeciﬁc hybrids derived
from backcrosses between Mus musculus and Mus spretus
[28]. Although the biparental mitochondrial DNA transmis-
sion is conﬁrmed in the interspeciﬁc F1 hybrid mice, the pater-
nal mitochondrial DNA is eliminated during early
embryogenesis in Mus musculus intraspeciﬁc hybrids [29]. In
other words, cytoplasmic genomes are transmitted uniparen-
tally in intraspeciﬁc crosses, and the leakage of paternalmitochondrial DNA is limited to interspeciﬁc crosses. Alterna-
tively, it is also possible that Sgce expression could be diﬀeren-
tially regulated in Mus musculus versus Mus spretus. In
addition, it is also possible that the age of the mice that were
used for the expression studies diﬀers between the two studies.
The 41 F1 hybrid mice we used included both sexes from 10 to
100 days postnatal. No detailed information of sex and age
was provided in the other study [15].
Despite accumulating clinical reports about the DYT11 dys-
tonic patients who have inherited the disease from aﬀected
mothers, no study has yet detected the switching of the mater-
nal to the paternal imprinting of SGCE. Furthermore, a myoc-
lonus-dystonic patient who inherited the mutated allele from
an aﬀected mother expressed only the wild-type paternal allele
inherited while the mutated maternal allele was silent [9]. Our
results on imprinting suggest that maternally inherited myoclo-
nus-dystonia may not be the result of the maternal expression
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manifestation may be due to mutations of DYT1 [30] or other
yet unidentiﬁed genes [31]. The results presented here could
contribute to the understanding of the pathogenesis of myoc-
lonus-dystonia because correctly identifying the mutant gene
is essential to uncovering the molecular and cellular mecha-
nisms underlying the pathophysiological changes associated
with myoclonus-dystonia.
We have cloned a family of novel type 3 Sgce mRNA vari-
ants and identiﬁed a novel alternatively spliced exon 11c. Sim-
ilar studies could be performed in human. Rescreen of the
homologous exon in patient DNA samples, where SGCE
mutations have been reported to be uncommon in phenotypic
myoclonus-dystonia patients [32–36], might yield new SGCE
mutations that are associated with this exon. Future research
directed at understanding the roles these mRNA variants play
in the brain could contribute to the understanding of the path-
ogenesis of DYT11 dystonia.
Additionally, we also found both type 2 and type 3 variants
had a PDZ-binding motif. PDZ-containing proteins are typi-
cally involved in the assembly of supramolecular complexes
that perform localized signaling functions at particular subcel-
lular locations [26]. For example, PSD-95 is usually located on
dendritic spines and is directly aligned with the active zone of
the presynaptic terminal. The type 2 and type 3 e-sarcoglycan
variants may be incorporated into supramolecular complexes
in the synapse by the PDZ-binding motif. A loss of PDZ-bind-
ing motifs may interfere with the binding of e-sarcoglycan to
its interacting proteins in the dystrophin-glycoprotein com-
plex. One of these partners may be syntrophin, a component
of dystrophin-glycoprotein complex that contains a PDZ do-
main that is crucial for the association of the nitric oxide syn-
thase with the complex [37,38]. Future studies directed at
identifying PDZ domain-containing proteins that interact with
e-sarcoglycans in the brain will shed light on the molecular
pathology underlying DYT11 dystonia.
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